(bnet.com): An editorial in the Journal of the American Medical Association describes a “disturbing example of inappropriate conduct” in studies for the GlaxoSmithKline’s diabetes drug Avandia. JAMA’s editorial calls for independent researchers to oversee all studies funded by drug companies to ensure that the data can be checked by someone not on the company payroll. JAMA already requires authors to disclose all payments when they publish in its pages.
Category: Articles
Click here